News Daily News Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure Michael O'Riordan December 30, 2025
News Daily News Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension Todd Neale October 07, 2025
News Daily News Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data L.A. McKeown July 24, 2025
News Daily News Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension L.A. McKeown July 14, 2025
News Daily News REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF Michael O'Riordan March 11, 2025
News Daily News CV Screening, Care at UK Football Club Made Inroads Against HF Caitlin E. Cox March 07, 2025
News Daily News Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF Michael O'Riordan March 03, 2025
News Daily News Sotagliflozin Reduces Ischemic Risk in SCORED Analysis Yael L. Maxwell February 25, 2025
News Daily News Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations L.A. McKeown January 31, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Daily News BMJ Investigation Revives Questions About PLATO, Ticagrelor Todd Neale December 20, 2024
News Daily News Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes Michael O'Riordan August 19, 2024
News Daily News CMS Announces Negotiated Medicare Prices for First 10 Drugs Yael L. Maxwell August 16, 2024
News Daily News Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors Yael L. Maxwell August 15, 2024
News Daily News COVID-19 Vaccination Tied to Fewer CV Events in Large UK Study Todd Neale August 01, 2024
News Daily News Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF Michael O'Riordan July 26, 2024
News Daily News Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA Caitlin E. Cox June 25, 2024
News Daily News Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds L.A. McKeown February 23, 2024